EZH2 and prostate cancer: Rottlerin has several pharmacological properties, many recently discovered, such as its antitumor activity, for example in tumor suppression through inhibition of EZH2 expression in prostate cancer cells, antitumor activity by inhibiting protein C kinase, tumor suppressor function by inhibiting the Cdc20 pathway in glioma cells, among others.